what pays the most in roulette In his poignant statement, Guardiola expressed his exhaustion with the constant grind of coaching at the highest level, stating, "I am tired. Mentally tired. It's been a long journey, full of challenges and triumphs, but it has also been draining. I need a break, a chance to recharge and rediscover my passion for the game."

One of the key highlights of Cloud Fast Charge's participation in the conference was the announcement of its strategic partnership with local stakeholders to deepen charging and battery replacement collaboration in Northern Anhui. The partnership aims to leverage Cloud Fast Charge's expertise in charging infrastructure and technology to enhance the accessibility and efficiency of electric vehicle services in the region. By working together with local partners, Cloud Fast Charge is poised to expand its footprint and create a seamless charging experience for electric vehicle users.Every car discontinued in Australia in 2024

Do they want Central rule in Maharashtra: Shiv Sena (UBT) slams Mahayuti over delay on CM faceIn Suarez's view, Emery's approach to man-management was a key factor in Arsenal's decline during his tenure. Suarez recounted instances where players felt undervalued and marginalized by Emery, leading to a lack of unity and team spirit within the squad. This toxic environment ultimately eroded the players' confidence and contributed to their underwhelming performances.

As "Reading on the Island" continues to captivate audiences with its unique blend of literature, travel, and reflection, it serves as a powerful reminder of the enduring power of storytelling and the transformative impact of reading. By returning to Hainan and championing a culture of reading among the people, the show not only enriches our intellectual lives but also strengthens our emotional connections to each other and the world around us. In a society that is often consumed by distractions and superficialities, "Reading on the Island" offers a welcome oasis of contemplation and inspiration, inviting us to slow down, reflect, and rediscover the beauty of the written word.Moreover, Jackson's response highlighted the power of forgiveness and understanding in the face of controversy and conflict. Rather than condemning Enzo for his controversial celebration, Jackson chose to offer support and encouragement, emphasizing the bigger picture of teamwork and mutual respect. His words served as a reminder that in the fast-paced and competitive world of professional sports, it is essential to prioritize unity and solidarity over individual achievements and egos.

It’s time for the holidays, which means robust family conversations and seemingly never-ending courses of food. But for the more tech-savvy among us, the journey home could also mean we’ll be called on to provide a backlog of tech support to parents, grandparents and other family members. And with generative AI being used to supercharge some major cyber scams this year, it’s also a good time to teach and not just fix. Here are some tips on how to manage your tech encounters this holiday season: Whether it’s Windows, macOS, iOS or Android, simply keeping your operating system and apps up-to-date will help protect your family’s computers and devices against a surprising number of security threats, such as malware, viruses and exploits. Most operating systems, especially those for mobile devices and their app stores, typically have auto-updates turned on by default. Be sure to double-check the device to make sure it has enough storage space to carry out the update. Keeping apps updated may also reduce the number of “Why isn’t this app working?” type of questions from your relatives. Chances are someone in your family is going to have a completely full mobile device. So full, in fact, that they can no longer update their phone or tablet without having to purge something first. There are many approaches to freeing up space. Here are a few you can easily take without having to triage data or apps. Use the cloud to back up media: Clear browsing data: According to some admittedly unscientific studies, the average person has hundreds of passwords. That’s a lot to remember. So as you help your relatives reset some of theirs, you may be tempted to recycle some to keep things simple for them. But that’s one of the bad password habits that cybersecurity experts warn against. Instead, try introducing your forgetful family member to a password manager. They’re useful tools for simplifying and keeping track of logins. And if you want to impress a more tech-savvy cousin or auntie, you could suggest switching to a more secure digital authentication method: passkeys. As scammers find new ways to steal money and personal information, you and your family should be more vigilant about who to trust. Artificial intelligence and other technologies are giving bad actors craftier tools to work with online. A quick way to remember what to do when you think you’re getting scammed is to think about the three S’s, said Alissa Abdullah, also known as Dr. Jay, Mastercard’s deputy chief security officer “Stay suspicious, stop for a second (and think about it) and stay protected,” she said. Simply being aware of typical scams can help, experts say. Robocalls frequently target vulnerable individuals like seniors, people with disabilities and people with debt. So-called romance scams target lonely and isolated individuals. Quiz scams target those who spend a lot of time on social media. Home internet speeds are getting faster, so you want to make sure your family members are getting a high-speed connection if they’ve paid for one. Run a broadband speed test on your home network if they’re still rocking an aging modem and router. Get local news delivered to your inbox!I’m A Celeb live chaos as viewers spot a string of awkward editing blunders

Ultimately, the fate of the Blue Moon hangs in the balance as the investigation into their alleged misconduct continues to unfold. Only time will tell how this saga will ultimately play out, but one thing is clear – Manchester City is facing a crisis of unprecedented proportions, and how they respond to it will determine the future course of the club.

FedEx Divests FedEx Freight and Shifts Gears to DRIVE Program

In today's rapidly evolving technological landscape, businesses and organizations are constantly seeking innovative solutions to streamline their processes, enhance efficiency, and stay ahead of the competition. One such solution that has been gaining rapid traction in recent years is the development of low-code platforms. These platforms enable users to create custom applications with minimal coding knowledge, significantly reducing development time and costs. One such cutting-edge platform that has been making waves in the industry is the 3D World Low-Code Platform.Is the NORAD Santa tracker safe from a government shutdown?USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Dec. 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights , underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases . This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care—particularly delays in screenings, diagnoses, and treatments—have likely exacerbated the progression of advanced disease, diminished survival rates, and complicated long-term data analysis. Still, the oncology field continues to push forward with promising developments emerging from key innovators like O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cardiff Oncology, Inc. (NASDAQ: CRDF), Personalis, Inc. (NASDAQ: PSNL), Tempus AI, Inc. (NASDAQ: TEM), and Checkpoint Therapeutics, Inc. (NASDAQ: CKPT). The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031 —a clear indicator of oncology's rapid growth and critical importance. Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers, which were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025 . "We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer," said Tom Heineman , M.D., Ph.D., Chief Medical Officer of Oncolytics . "Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer. This offers the promise of delaying disease progression and improving survival in patients with these devasting diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients." Oncolytics will present two key data sets from the GOBLET study, with preliminary safety and tumor response results for the relapsed anal carcinoma cohort treated with pelareorep and atezolizumab presented in Poster Session C on January 25, 2025 , from 7:00 to 7:55 a.m. PT . Additionally, results from the safety run-in phase for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, with and without atezolizumab will be presented in Poster Session B on January 24, 2025 , from 11:30 a.m. to 1:00 p.m. PT . Both abstracts will be available on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025 . CONTINUED... Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). Efficacy and safety data are for all evaluable patients as of a November 26, 2024 , data cut-off date, and all efficacy data are determined by a blinded, independent central review (BICR) of each patient's tumor scan. "We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial," said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology . "Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses." Personalis, Inc. (NASDAQ: PSNL), a developer of advanced cancer genomic tests and analytics, and Tempus AI, Inc. (NASDAQ: TEM), an AI-powered healthcare technology company, recently announced they've expanded their commercial relationship. Both companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. "While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus' integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products," said Chris Hall , CEO of Personalis . "We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity." Under this expanded relationship, Tempus will be enabled to offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers who wish to bundle MRD testing with other Tempus offerings in a given study. Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), a commercial-stage immunotherapy and targeted oncology company focused on novel treatments for patients with solid tumor cancers, recently announced that the FDA approved its UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. "[This] FDA approval of UNLOXCYT – the first marketing approval for our company – is a significant milestone both for Checkpoint and for patients with advanced cSCC," said James Oliviero , President and CEO of Checkpoin t. "This approval marks Checkpoint's transformation to a commercial-stage company, with the opportunity to compete in a U.S. market estimated to exceed $1 billion annually, where we believe UNLOXCYT offers a differentiated treatment option versus available therapies by binding to PD-L1, rather than programmed death receptor-1 (PD-1), to release the inhibitory effects of PD-L1 on the anti-tumor immune response. Additionally, UNLOXCYT has demonstrated the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), another potential differentiating feature of the drug compared to existing marketed therapies for patients with cSCC." Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content: https://www.prnewswire.com/news-releases/oncology-advancements-accelerate-amid-rising-early-onset-cancer-diagnoses-302337555.html SOURCE USA News Group

Kane’s hat-trick sends Bayern 8 points clearNEW YORK (AP) — Shohei Ohtani won his third Most Valuable Player Award and first in the National League, and Aaron Judge earned his second American League honor on Thursday. Ohtani was a unanimous MVP for the third time, receiving all 30 first-place votes and 420 points in voting by the Baseball Writers’ Association of America. New York Mets shortstop Francisco Lindor was second with 263 points and Arizona second baseman Ketel Marte third with 229. Judge was a unanimous pick for the first time. Kansas City shortstop Bobby Witt Jr. got all 30 second-place votes for 270 points, and Yankees outfielder Juan Soto was third with 21 third-place votes and 229 points. Judge had discussed the MVP award with Philadelphia’s Bryce Harper, the NL winner in 2015 and ’21. “I was telling him, `Man, I’m going to try to catch up to you with these MVPs here, man,’” Judge recalled. “He’d say, hopefully, he could stay a couple ahead of me, which I think he’ll do.” Ohtani was unanimously voted the AL MVP in 2021 and 2023 as a two-way star for the Los Angeles Angels and finished second to Judge in 2022 voting . He didn’t pitch in 2024 following elbow surgery and signed a record $700 million, 10-year contract with the Los Angeles Dodgers last December. He was the first player to twice become an unanimous MVP. He combined with Atlanta outfielder Ronald Acuña Jr. in 2023 for the first year both MVPs were unanimous. Ohtani hit .310, stole 59 bases and led the NL with 54 homers and 130 RBIs exclusively as a designated hitter, becoming the first player with 50 or more homers and 50 or more stolen bases in a season. He helped the Dodgers to the World Series title , playing the final three games with a torn labrum in his left shoulder . Ohtani became the first primary DH to win an MVP. He joined Frank Robinson for Cincinnati in 1961 and Baltimore in 1966 as the only players to win the MVP award in both leagues. Ohtani is the 12th player with three or more MVPs, joining Barry Bonds (seven) and Jimmie Foxx, Joe DiMaggio, Stan Musial, Roy Campanella, Yogi Berra, Mickey Mantle, Mike Schmidt, Alex Rodriguez, Albert Pujols and Mike Trout (three each). Balloting was conducted before the postseason. Judge led the major leagues with 58 homers, 144 RBIs and 133 walks while hitting .322. Witt topped the big leagues with a .332 average, hitting 32 homers with 31 stolen bases and 109 RBIs. Soto batted .288 with 41 homers and 109 RBIs. When Judge won his first MVP award in 2022, he received 28 first-place votes while Ohtani got the other two. When Judge won his first MVP award in 2022, he received 28 first-place votes while Ohtani got the other two. He is the Yankees' 22nd MVP winner, four more than any other team. Judge was hitting .207 with six homers and 18 RBIs through April, then batted .352 with 52 homers and 126 RBIs in 127 games. “March and April were not my friend this year.” Judge said. “Just keep putting in the work and things are going to change. You can’t mope. You can’t feel sorry for yourself. Especially in New York, nobody’s going to feel sorry for you. So you just got to go out there and put up the numbers?” Balloting was conducted before the postseason. AP MLB: https://apnews.com/MLB

South Korea's National Assembly recently passed a resolution for the swift arrest of former Prosecutor General Yoon Seok-yeol, sending shockwaves throughout the nation. This development has thrown the country into a political crisis, with President Moon Jae-in facing mounting pressure and uncertainty.

As South Korea grapples with the aftermath of President Yoon's arrest, the country faces a critical juncture in its history. The coming days and weeks will be crucial in determining the path forward for the nation and in shaping its political landscape for years to come.The highly anticipated showdown between "Hunt 1" and "Hunt 2" has sent shockwaves throughout the entertainment industry. Fans of both series are eagerly counting down the days until the epic battle unfolds on screen.

Registration for the MarsCode AI Programming Challenge is now open to programmers, developers, and AI enthusiasts of all levels. Whether you are a seasoned AI expert or a newcomer to the field, this competition offers a unique opportunity to showcase your talent, explore new ideas, and be part of a dynamic community of innovators.We Found 15 Perfect Ways To Give A Uniquely Personal Present This Holiday Season

None

Exciting news for fans of action-adventure games, the highly-anticipated game "Black Myth: Wukong" has officially announced a new update, revealing exciting challenges, gameplay features, and travel maps. Developed by Chinese indie studio Game Science, "Black Myth: Wukong" has been generating buzz for its stunning visuals, innovative gameplay, and immersive storytelling inspired by the classic Chinese novel Journey to the West. Let's delve into the newly announced updates and what players can expect from this epic journey.Company will implement innovative Mission Partner Environment to securely share information with global mission partners FALLS CHURCH, Va. , Dec. 20, 2024 /PRNewswire/ -- General Dynamics Information Technology (GDIT), a business unit of General Dynamics GD , announced today it was awarded a new $5.6 billion contract by the Air Force Mission Partner Capabilities Office. The single award, indefinite-delivery indefinite-quantity contract, awarded in November, has a five-year base period and a five-year option. Mission Partner Environments (MPEs) enable the military and its trusted partners to securely communicate, collaborate and share information at multiple levels of classification in real time so decision makers can rapidly adapt to changing mission dynamics. Under the contract, GDIT will modernize, integrate, operate and sustain the Department of Defense's MPE. The company will provide a portfolio of services including mission, cyber and enterprise IT services and infrastructure. This contract will also advance interoperability – the ability to seamlessly connect multiple systems together – with U.S. government and non-government entities and international coalition partners in support of the National Defense Strategy. "The complexity of global threats necessitates the urgency to create agile, secure and seamless information-sharing environments with our trusted partners," said Amy Gilliland , GDIT's president. "We look forward to implementing an integrated Mission Partner Environment that will serve as a blueprint for future efforts across the Department of Defense." GDIT has more than three decades of experience delivering some of the largest MPE programs globally. This includes operating the largest coalition intelligence sharing program in the world as well as implementing an MPE network for U.S. Army Europe and Africa . At Talisman Sabre 2023, the company also demonstrated the first ever Zero Trust exercises to enable rapid, secure and seamless data sharing between global mission partners in battlefield environments with limited to no internet connectivity. GDIT is a business unit of General Dynamics, a global aerospace and defense company that offers a broad portfolio of products and services in business aviation; ship construction and repair; land combat vehicles, weapons systems and munitions; and technology products and services. General Dynamics employs more than 100,000 people worldwide and generated $42.3 billion in revenue in 2023. More information about General Dynamics Information Technology is available at www.gdit.com . More information about General Dynamics is available at www.gd.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/gdit-awarded-mission-partner-environment-contract-302337479.html SOURCE General Dynamics © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.